Back to search

National and Kapodistrian University of Athens

Η συσχέτιση ιστοπαθολογικών, κλινικών και ορμονολογικών παραγόντων σε επινεφριδιακά νεοπλάσματα

Abstract

dc:description

Adrenocortical carcinoma (ACC) is a rare but very aggressive endocrine malignancy with poor 5-year survival rates. An accurate diagnosis is critical, because the prognosis, follow up and therαpeutic strategy for ACC are very different to those for a benign tumor. Histopathology is important for diagnosis, while immunohistochemistry markers and gene profiling of the resected tumor may sometimes be superior to current staging systems to determine prognosis. In the current study, we aimed to present the 20year experience at a tertiary Hospital in patients with ACCs and correlate the immunohistochemical characteristics of ACCs with the clinical – morphological data and the survival of patients. A total of 45 patients with adrenocortical carcinomas op ERαted on in a single center were included in the study. They were part of a series of 758 cases of adrenalectomies performed for various tumors of the adrenal gland. The size and weight of the tumors were examined as also the Weiss score system and the ENSAT classification. Expression of the following markers was examined in the tumors with Weiss score > 3: Inhibin-a, Melan A, Calretinin, Ki67, Synaptophysin, Chromogranin A, p53, Vimentin, CKAE1/AE3 and in some cases SF-1 has also been performed. Of a total of 45 patients who were diagnosed with ACC the majority were female (1.37:1) with a median age of 55.5 years (IQR 19-77) at diagnosis. Clinical follow up was available for 38 out of 45 patients with a median follow up period of 18 months (IQR 1-96). ENSAT stage I, II, III and IV was 6.6%, 62.3%, 26.7% and 4.4%, respectively. Seven patients (15.5%) lost to follow up, 12 patients (31.58%) had ≤1-year survival and 17 (44.74%) demonstrated ≤ 5-year survival. Survival was significantly higher in patients with stage I–II as compared to patients with stage III–IV ACC (62 ± 8.7months vs 31 ± 12.1 months, p=0.02). The median size of ACCs was 9cm (IQR 3.5-22cm) and the median weight 127gr (IQR 18-1400gr). Both volume and weight were higher in right-sided lesions reaching statistical significance (p=0.008 and p=0.07 respectively). A significant correlation between tumor volume (p=0.011, r=0.418), diameter (p=0.005, r=0.449), weight (p=0.04, r=0, 339) and Weiss score was observed. The expression of Ki67 was positively correlated with Weiss score (p=0.25, r=0.383). There was also an association between Weiss score and the expression of vimentin and synaptophysin (p=0.02 and p=0.07 respectively). A larger tumor diameter >10 cm (p=0.007), tumor volume >500 cm3 (p=0.0003), tumor weight >300 gr (p=0.03), Ki-67 index >4% (p=0.04), Weiss score >5 (p=0.001), Helsinki score >8 (p=0.06) were significantly associated with lower ov ERαll survival (OS) in the univariable analysis. On the contrary, the expression of Melan A and lower expression of Ki-67 (≤4) were independently associated with longer OS time (p=0.01). No statistical significance was observed regarding the correlation between IHC markers and ENSAT staging (I/II vs III/IV). The vast majority of adrenal tumors are benign (adenomas) while adrenocortical carcinomas (ACC) are rare with a very poor prognosis. Previous studies indicated that estrogens play an important role in the etiology and progression of sev ERαl endocrine-related neoplasms such as adrenocortical tumors. Estrogen exert genomic activities through the nuclear estrogen-receptor (ER) subtypes α and β, while the non-genomic effects are mediated by membrane-bound-G-protein-coupled-ER-30 (GPR30). Though estrogens induce cancer cell prolif ERαtion through ERα, ERβ appears to exert a protective effect. Recently, in vitro experiments showed that treatment with ER-α antagonist as well as GPER30 agonist reduces prolif ERαtion in H295R cells. However, data on the expression profile of ERs in normal and neoplastic human adrenocortical neoplasms is limited. Additionally, epidermal growth factor receptor (EGFR) has been shown to be highly expressed in ACC but not in adrenocortical adenomas. The expression of EGFR has been negatively correlated with expression of ER in breast cancer, while there is no data available regarding the correlation between ERs and EGFR expression in adrenocortical neoplasms. In our study we aimed to investigate the expression profile of ERs and EGFRs in adrenocortical neoplasms and correlate it with their biological behavior.Total RNA was extracted from fresh frozen tissue of: eight non functional adenomas (NFA), eight cortisol producing adenomas (CPA), their adjacent normal adrenal tissues (NAC) AND eight adrenocortical carcinoma (ACC). The expression of ERα, ERβ, GPR30 and EGFR genes was evaluated by qPCR. The Immunohistochemistry(IHC) was performed to evaluate the EGFR and GPR30 protein levels. The expression of both ERα and GPR30 were higher in the CPA as compared to it’s paired NAC group (p<0.05) while there was no significant difference in ERβ and EGFR mRNA levels between CPA, NFA and their adjacent normal tissues. The expression of GPR30 was significantly higher in ACC as compared to either NFA or NAC groups (p<0.05) and marginally higher in ACC as compared to CPA. Moreover, the expression of ERα and EGFR was higher reaching its significance in ACC as compared to either CPA or NFA (p<0.1). IHC revealed that the expression of EGFR was significantly higher in ACC compared to the adrenal benign tumors. A marginal positive correlation between EGFR and GPER-30 expression was observed in ACC. To our knowledge this is the first study to evaluate the expression of membrane-bound GPR30 in human adrenocortical neoplasms. Our preliminary data suggest a possible role of GPR30 and EGFR in adrenocortical malignancy. However, further studies with larger numbers of samples are required to draw conclusions about the exact role of ERs and EGFR on adrenal tumorigenesis. Adrenocortical carcinoma is a rare and very aggressive endocrine malignancy. The most important clinical factors that determine long-term prognosis of ACC are the disease stage at diagnosis and the completeness of surgical resection. The presented data indicate that immunohistochemical assessment may also provide useful information, contributing in the diagnosis and treatment of ACCs.

Degree

thesis:*
Grantor dc:publisher
National and Kapodistrian University of Athens
Year dc:date
2022

Author and committee

dc:creator, dc:contributor.*
Authors dc:creator
  • Parianos, Christos
  • Παριανός, Χρήστος

Subjects

dc:subject × 8

Rights

Language dc:language
gre

Identifiers

dc:identifier.*
Identifier
10.12681/eadd/52611

Chain of custody

source
Harvested from
Greek National Archive of PhD Theses
Base URL
phdtheses.ekt.gr/eadd_oai/request
Last updated
2026-11-18
Source record
OAI-PMH GetRecord
citation

Parianos, Christos; Παριανός, Χρήστος. Η συσχέτιση ιστοπαθολογικών, κλινικών και ορμονολογικών παραγόντων σε επινεφριδιακά νεοπλάσματα. National and Kapodistrian University of Athens, 2022. http://hdl.handle.net/10442/hedi/52611